Compare Five Below Inc (FIVE) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs IDEXX Laboratories, Inc. — how do they compare? Five Below Inc trades at $209.72 (market cap $11.25B), while IDEXX Laboratories, Inc. trades at $512.76 (market cap $39.92B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.5× Five Below Inc's market cap, and Five Below Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| FIVE | IDXX | |
|---|---|---|
Market Cap | $11.25B | $39.92B |
Volume | 986,546 | 715,982 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $766.68 |
52-Week Low | $138.49 | $504.70 |
Typical Hold Time | 46 Days | 46 Days |
Enterprise Value | $12.10B | $40.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $209.56, down 0.17% on the day, with a bearish technical signal despite bullish oscillators. The company shows strong profitability with 40.26% gross margins and 28.25% ROE, though net margins declined to 6.54% in 2025. Recent earnings beats and a raised 2026 outlook highlight growth momentum, supported by store expansion and digital initiatives. Cash flow improved significantly in 2025 with $152M net inflow after two years of negative flows.
The stock offers substantial upside to the $298.44 consensus target, with 60% analyst buy ratings and no sell recommendations. Key risks include premium valuation (P/E 18.32) and execution pressure amid consumer spending concerns. Growth catalysts include the $600M buyback and store revamp strategy, though technical resistance near $212 may limit near-term gains.
IDEXX Laboratories (IDXX) trades at $513.14, down 0.44% with bearish technical signals despite strong fundamentals. The company demonstrates robust revenue growth, expanding from $3.4B in 2022 to $4.3B in 2025, with net income reaching $1.06B. Recent acquisitions like CoVetAI and diagnostic platform expansions highlight strategic growth initiatives. Technical indicators show oversold conditions with RSI at 26.58, while moving averages signal bearish momentum. Analyst consensus remains optimistic with a $665 price target representing 30% upside potential.
The outlook remains positive given strong earnings beats, expanding profit margins, and strategic acquisitions. However, risks include technical weakness, FX headwinds, and competitive pressures. With 56.5% analyst buy ratings and institutional accumulation, IDXX offers growth potential but requires monitoring of technical support levels near $492-$502 for entry opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
